Seraph 100 Microbind Affinity Blood Filter
Scanning electron microscopy of S. aureus Newman attached to Seraph 100 functional media1
1. Seffer et al, Staphylococcus aureus Binding to Seraph® 100 Microbind® Affinity Filter: Effects of Surface Protein Expression and Treatment Duration, PLOS One, 2023;18(3):1-14
Our Technology
ExThera’s proprietary Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) was the first and only pathogen adsorption therapy available under Emergency Use Authorization (EUA) in the United States to treat patients 18 years of age or older with confirmed Coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure to reduce pathogens and inflammatory mediators from the bloodstream.
ExThera Medical’s extracorporeal products are in development for patients suffering from severe infections. Products are also being developed for the treatment of metastatic cancer.
What is Seraph 100 capable of?
Seraph 100 functions by reducing pathogens in the bloodstream.
Funded Collaboration Courtesy of the United States Defense Advanced Research Programs Agency (DARPA)
ExThera’s technology was evaluated in a collaborative research program with Battelle Memorial Institute with the goal of developing a dialysis-like therapeutic (DLT) intrinsic separation device to treat sepsis in wounded warriors—all funded by a grant from DARPA.
ExThera had the only device evaluated in the final phase of the competitive program after other technologies were “down selected” because they were unable to meet the program’s goals. Because of ExThera Medical’s participation, DARPA considers the DLT program a success.
MM-00070 Rev G